In March, 2024, an Advisory Group of 28 independent scientists from 22 countries met in Lyon, France to recommend priorities for carcinogenicity evaluations by the International Agency for Research on Cancer (IARC) Monographs programme during 2025–29. IARC periodically convenes such advisory groups to ensure that the agents evaluated in the Monographs are selected on the basis of the latest scientific evidence relevant to carcinogenicity.1 A detailed report of the Advisory Group recommendations will be published in due course.